Abstract 734P
Background
In RUBY (NCT03981796), dostarlimab (D)+carboplatin-paclitaxel (CP) demonstrated significant OS benefits vs placebo (PBO)+CP in pts with pA/rEC. Differential response rates alone insufficiently describe the impact on long-term outcomes, in part because of high response rates with CP, albeit with a lack of durability. Response-based modeling may describe OS benefits associated with D+CP. This analysis investigated the impact of response on OS in the intent-to-treat population of RUBY.
Methods
In this post hoc exploratory OS analysis, surviving pts with evaluable disease were grouped by investigator-assessed objective response at 3 months (3-mo landmark). Landmarking eliminates immortal time bias. Pts with complete/partial response were classified as responders; those with stable or progressed disease were classified as nonresponders. Postlandmark OS was assessed using Kaplan-Meier methods and Cox proportional hazards models. Landmark analyses based on response at 1.5 or 4.5 mo were explored in sensitivity analyses.
Results
Overall, 196 pts in D+CP and 200 in PBO+CP were evaluable; 122 and 107, respectively, were responders; 74 and 93, respectively, were nonresponders at the 3-mo landmark. For responders, median (mo [95% CI]) postlandmark OS was not reached (NR) for D+CP (NR [NR-NR]) or PBO+CP (NR [18.5-NR]). For nonresponders, median OS was NR (21.6-NR) for D+CP and 26.8 (15.2-NR) for PBO+CP. HRs and postlandmark OS probabilities are shown in the table. Sensitivity analyses yielded similar results.
Conclusions
Outcomes associated with response to dostarlimab+CP were favorable compared with response to PBO+CP, reflecting the improved durability of benefit. OS rates suggest potential long-term benefits in responders and nonresponders. These findings provide further support for the use of D+CP as a standard of care in pts with pA/rEC. Table: 734P
Postlandmark OS rates among responders and nonresponders
Responders | Nonresponders | |||
D+CP | PBO+CP | D+CP | PBO+CP | |
3-mo landmark, n | 122 | 107 | 74 | 93 |
12-mo OS, % | 88 | 82 | 71 | 68 |
18-mo OS, % | 78 | 64 | 66 | 57 |
Median (95% CI), mo | NR (NR-NR) | NR (18.5-NR) | NR (21.6-NR) | 26.8 (15.2-NR) |
HR (95% CI) | 0.50 (0.31-0.81) | 0.76 (0.46-1.25) | ||
Sensitivity analyses | ||||
1.5-mo landmark, n | 121 | 112 | 78 | 95 |
12-mo OS, % | 87 | 80 | 73 | 71 |
18-mo OS, % | 80 | 63 | 67 | 57 |
Median (95% CI), mo | NR (NR-NR) | 22.6 (19.9-NR) | NR (23.1-NR) | 28.3 (16.7-NR) |
HR (95% CI) | 0.48 (0.30-0.77) | 0.76 (0.46-1.23) | ||
4.5-mo landmark, n | 116 | 104 | 70 | 82 |
12-mo OS, % | 87 | 75 | 73 | 70 |
18-mo OS, % | 78 | 61 | 69 | 59 |
Median (95% CI), mo | NR (NR-NR) | NR (17.5-NR) | NR (21.3-NR) | 25.3 (15.3-NR) |
HR (95% CI) | 0.52 (0.32-0.85) | 0.79 (0.46-1.35) |
Clinical trial identification
NCT03981796.
Editorial acknowledgement
Medical editorial assistance was provided by Nucleus Global, an Inizio company, and funded by GSK.
Legal entity responsible for the study
GSK.
Funding
This study was funded by GSK.
Disclosure
M.R. Mirza: Financial Interests, Personal, Advisory Role: AstraZeneca, Biocad, GSK, Karyopharm, Merck, Roche, Zailab; Financial Interests, Personal, Speaker’s Bureau, Honoraria: AstraZeneca, GSK; Financial Interests, Personal, Stocks or ownership: Karyopharm; Financial Interests, Institutional, Research Funding: Apexigen, AstraZeneca, GSK, Ultimovacs; Financial Interests, Institutional, Research Funding, Trial Chair: Deciphera ; Financial Interests, Personal, Member of Board of Directors: Karyopharm. C. Mathews: Financial Interests, Institutional, Research Funding: AvengeBio Astellas Pharma, AstraZeneca, Deciphera, EMD Serono, Genentech, Genmab, GSK, Merck, Moderna, The National Cancer Institute, Regeneron, Seagen, Syros. A. Koliadi: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, GSK. L. Gilbert: Financial Interests, Institutional, Research Grant: Alkermes, AstraZeneca, Clovis, Corcept Therapeutics, Esperas, GOG Foundation, GSK, ImmunoGen, IMV, Karyopharm, K-Group Beta, Merck Sharp &Dohme, Mersana Therapeutics, Novocure GmbH, OncoQuest Pharmaceuticals, Roche, Shattuck Labs, Sutro BioPharma, Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Merck; Financial Interests, Personal, Speaker’s Bureau, Honoraria: CanariaBio, Eisai, Eisai-Merck, GOG Foundation, GSK, ImmunoGen, Kora Healthcare, Merck; Financial Interests, Personal, Financially compensated role, Support for attending meetings and/or travel: EndomEra, GOG Foundation, GSK, Merck, Zentalis; Financial Interests, Personal, Advisory Board: CanariaBio, Eisai, Eisai-Merck, GOG Foundation, GSK, ImmunoGen, Kora Healthcare, Merck. B.M. Slomovitz: Financial Interests, Personal, Speaker, Consultant, Advisor: Aadi Biosciences, AstraZeneca, BioNTech, Clovis Oncology, Eisai, Genmab, Genentech, Gilead, GSK, Incyte, Karyopharm, Merck, Novartis, Novocure, Regeneron, Seagen; Financial Interests, Personal, Speaker’s Bureau, Honoraria: Seagen. B.J. Monk: Financial Interests, Personal, Speaker, Consultant, Advisor: Agenus, Akeso Biopharma, Amgen, Aravive, Bayer, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, ImmunoGen, Iovance, Karyopharm, MacroGenics, Mersana, Myriad, Novartis, Novocure, Pfizer, Puma, Regeneron, Sorrento, US Oncology Research, VBL; Financial Interests, Personal, Speaker’s Bureau, Honoraria: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Clovis, Eisai, Merck, Roche/Genentech, Tesaro/GSK. P. Braly: Financial Interests, Institutional, Research Funding: GSK. D. Black: Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Personal, Membership or affiliation, Membership fees: GOG Partners Investigational Council ; Financial Interests, Personal, Other, Medical Director/ Owner: Trials365, LLC. S.J. Lubinga: Financial Interests, Personal, Full or part-time Employment: GSK; Financial Interests, Personal, Stocks/Shares: GSK. D.J. Sharpe: Financial Interests, Institutional, Full or part-time Employment: Parexel International; Financial Interests, Institutional, Other, Organization received funds to conduct statistical research: Bristol Myers Squibb, GSK. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Clovis Oncology, Eisai, GSK, Merck, Seagen, Tesaro. All other authors have declared no conflicts of interest.
Resources from the same session
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01
672P - Inference failure with synthetic arms: Empirical application to phase III oncology trials
Presenter: Alexander Decruyenaere
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01